Use of egf to inhibit pathogenic infections of the urogenital tract
CA 2464609 A1 · Owner: University Technologies International, Inc. · Inventors: Olson, Merle E.; Gall, D. Grant; Hardin, James A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention relates to treating or preventing pathogenic infections with an epidermal growth factor (EGF). EGF is capable of inhibiting pathogenic colonization of pathogens in a variety of tissue or cell types. Since pathogenic colonization is essential for pathogenic infection EGF can be used , as an effective preventive and therapeutic agent for pathogenic infections particularly in the urogenital tract.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 25, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 25, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 25, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.